U.S. Government Takes Herpes Vaccine Development Lead
Apr 4, 2024 · Washington DC (Precision Vaccinations News). Herpes simplex viruses (HSV) are widely known to cause viral infections such as blisters around the face, and genital herpes usually affects the genital and buttocks area.
Multi-Country Herpes Immunotherapy Clinical Study Continues
Mar 5, 2024 · A leading global vaccine developer has announced that their investigational vaccine candidate for Herpes Simplex Virus (HSV) is undergoing a phase 1/2 clinical trial for the first time in Europe, England, and the United States. GlaxoSmithKline plc. (GSK), known for its extensive range of vaccines for various conditions, including RSV, meningitis, and shingles, is …
HSV Treatment Readies for Approval — Precision Vaccinations News
Mar 29, 2023 · Pritelivir is a nonnucleoside helicase primase inhibitor against HSV. Germany (Precision Vaccinations News). A recently published Original Article reported positive news regarding the First-in-Human clinical trials assessing Pritelivir, a Nonnucleoside Helicase-Primase Inhibitor targeting the Herpes Simplex Virus (HSV).
34 Countries Identified in the Latest Polio Outbreak Alert
The Global Polio Eradication Initiative (GPEI) released its weekly update, which indicated that three countries reported new polio cases as the poliovirus continues to spread in 2024. On June 19, 2024, the GPEI reported that Afghanistan confirmed one wild poliovirus type 1 (WPV1), bringing the total number of cases in 2024 to six. Nigeria reported three cases of circulating …
Herpes Vaccine Candidate Advances in 2023 - Precision …
Jan 8, 2023 · When BioNTech SE announced that the first person was dosed in a first-in-human Phase 1 clinical trial with BNT163, a herpes simplex virus (HSV) vaccine candidate for the prevention of genital lesions caused by HSV-2 and potentially HSV-1, there was much enthusiasm generated by millions of people. BioNTech's placebo-controlled, observer-blinded, two-dose …
mRNA-Based Flu Shot Focuses on Improving Performance in …
Apr 4, 2024 · As influenza vaccine producers prepare for the 2024 - 2025 flu season, innovative vaccine candidates are progressing in clinical research, focused on enhancing efficacy and safety. CureVac N.V. today announced interim data from an ongoing Phase 2 study, which is part of the combined Phase 1/2 study of its seasonal influenza vaccine candidate.
Dengue Antiviral Development Discontinued — Precision …
Oct 7, 2024 · (Precision Vaccinations News) Millions of people will be infected with the Dengue virus in the last few months of 2024 without being able to be treated with an approved antiviral.. Johnson & Johnson (J&J) announced on October 4, 2024, that it discontinued the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir (JNJ-1802) for …
What’s the Difference Between Shingles and Chickenpox Vaccines?
Nov 2, 2017 · Shingrix shingles vaccine contains a lone protein isolated from the shell of the varicella zoster virus
After Nine Years, Oral Spray UTI Vaccine Remains Highly Effective
Apr 7, 2024 · Madrid (Precision Vaccinations News). A recent study presented at the European Association of Urology Congress shared the initial findings of the first long-term follow-up study on the safety and effectiveness of the Uromune™ (MV140) inactivate vaccine for recurrent Urinary Tract Infections (UTIs).. The results, announced on April 6, 2024, indicate that 54% of study …
U.S. CDC Vaccine Committee Meets Tomorrow
2 days ago · The U.S. CDC's Advisory Committee on Immunization Practices (ACIP) is scheduled to review scientific data and vote on vaccine recommendations on October 23-24, 2024. Dr. Keipp Talbot, ACIP Chair, will lead this ACIP meeting from Atlanta, GA. The final agenda includes presentations on chikungunya, HPV, influenza, pneumococcal, and RSV vaccines. These …
- Some results have been removed